AVBP Valuation
Arrivent Biopharma Inc
$
19.350
- Overview
- Forecast
- Valuation
AVBP Relative Valuation
AVBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVBP is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AVBP's competitors is 3.39, providing a benchmark for relative valuation. Arrivent Biopharma Inc Corp (AVBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
GCT
GigaCloud Technology Inc
18.525
USD
-1.88%
IE
Ivanhoe Electric Inc
6.750
USD
-1.32%
OSBC
Old Second Bancorp Inc
17.080
USD
-0.12%
ICLK
iClick Interactive Asia Group Ltd
9.240
USD
+9.09%
BVS
Bioventus Inc
6.930
USD
+2.06%
TYRA
Tyra Biosciences Inc
9.680
USD
-3.10%
TSAT
Telesat Corp
16.610
USD
-1.10%
GLDD
Great Lakes Dredge & Dock Corp
10.990
USD
-1.88%
LVWR
LiveWire Group Inc
1.160
USD
0.00%
SCVL
Shoe Carnival Inc
20.070
USD
-0.94%
FAQ
Is Arrivent Biopharma Inc (AVBP) currently overvalued or undervalued?
Arrivent Biopharma Inc (AVBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Arrivent Biopharma Inc (AVBP) is between to according to relative valuation methord.
What is Arrivent Biopharma Inc (AVBP) fair value?
How does AVBP's valuation metrics compare to the industry average?
What is the current P/B ratio for Arrivent Biopharma Inc (AVBP) as of May 20 2025?
What is the current FCF Yield for Arrivent Biopharma Inc (AVBP) as of May 20 2025?
What is the current Forward P/E ratio for Arrivent Biopharma Inc (AVBP) as of May 20 2025?